![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
C-EDGE: HEAD 2 HEAD - Efficacy and Safety of Elbasvir/Grazoprevir versus Sofosbuvir /Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and Prior PR Treatment Failure Subjects with Chronic HCV GT1 or 4 Infection
|
|
|
Reported by Jules Levin
EASL 2016 Barcelona April 14-17
Jan Sperl, Gabor Horvath, Waldemar Halota, Juan Arenas Ruiz-Tapiador, Anca Streinu-Cercel, Ligita Jancoriene, Klara Werling, Hege Kileng, Seyfettin Koklu, Jan Gerstoft, Sushma Patel, Jingjun Qiu, Ernest Assante-Appiah, Janice Wahl, Bach-Yen Nguyen, Eliav Barr, Heather L. Platt
![conclusion](../images/041516/041516-3/conclusion.gif)
![EASL2](../images/041516/041516-3/EASL2.gif)
![EASL3](../images/041516/041516-3/EASL3.gif)
![EASL4](../images/041516/041516-3/EASL4.gif)
![EASL5](../images/041516/041516-3/EASL5.gif)
![EASL6](../images/041516/041516-3/EASL6.gif)
![EASL7](../images/041516/041516-3/EASL7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|